BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10963203)

  • 1. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma.
    Wagner SN; Rebmann V; Willers CP; Grosse-Wilde H; Goos M
    Lancet; 2000 Jul; 356(9225):220-1. PubMed ID: 10963203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy.
    Ugurel S; Rebmann V; Ferrone S; Tilgen W; Grosse-Wilde H; Reinhold U
    Cancer; 2001 Jul; 92(2):369-76. PubMed ID: 11466692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The adjuvant treatment of malignant melanoma.
    Reintgen D; Kirkwood J
    J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
    Jonasch E; Kumar UN; Linette GP; Hodi FS; Soiffer RJ; Ryan BF; Sober AJ; Mihm MC; Tsao H; Langley RG; Cosimi BA; Gadd MA; Tanabe KK; Souba W; Haynes HA; Barnhill R; Osteen R; Haluska FG
    Cancer J; 2000; 6(3):139-45. PubMed ID: 10882328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the role of adjuvant interferon for high risk melanoma.
    Agarwala SS; Kirkwood JM
    Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.
    Kirkwood JM; Richards T; Zarour HM; Sosman J; Ernstoff M; Whiteside TL; Ibrahim J; Blum R; Wieand S; Mascari R
    Cancer; 2002 Sep; 95(5):1101-12. PubMed ID: 12209697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose adjuvant interferon therapy for melanoma.
    Licata AG
    Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interferon for adjuvant therapy in melanoma; although approved, not indicated].
    Groenewegen G; Osanto S; van der Rhee HJ; Punt CJ
    Ned Tijdschr Geneeskd; 2000 Nov; 144(45):2160-2. PubMed ID: 11086492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant high-dose interferon alfa-2b.
    Fluck M; Kamanabrou D; Lippold A; Reitz M; Atzpodien J
    Cancer Biother Radiopharm; 2005 Jun; 20(3):280-9. PubMed ID: 15989473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphatic mapping and sentinel node biopsy in patients with malignant melanoma.
    Reintgen D; Rapaport D; Tanabe KK; Ross M
    J Fla Med Assoc; 1997 Mar; 84(3):188-93. PubMed ID: 9143171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse.
    Gale DM; Kiley KE
    Clin J Oncol Nurs; 1998 Jan; 2(1):5-10. PubMed ID: 9481250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High density oligonucleotide array analysis of interferon- alpha2a sensitivity and transcriptional response in melanoma cells.
    Certa U; Seiler M; Padovan E; Spagnoli GC
    Br J Cancer; 2001 Jul; 85(1):107-14. PubMed ID: 11437411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
    McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
    Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma.
    Donnelly S
    Oncol Nurs Forum; 1998 Jun; 25(5):921-7. PubMed ID: 9644709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice.
    Ravaud A; Bedane C; Geoffrois L; Lesimple T; Delaunay M
    Br J Cancer; 1999 Aug; 80(11):1767-9. PubMed ID: 10468294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.
    Kirkwood JM; Tarhini AA; Moschos SJ; Panelli MC
    Nat Clin Pract Oncol; 2008 Jan; 5(1):2-3. PubMed ID: 18030300
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant high-dose interferon revisited.
    Sondak VK; Flaherty LE
    Cancer J; 2000; 6(3):132-4. PubMed ID: 10882326
    [No Abstract]   [Full Text] [Related]  

  • 19. Who benefits most from adjuvant interferon treatment for melanoma?
    Gogas H; Abali H; Ascierto PA; Demidov L; Pehamberger H; Robert C; Schachter J; Eggermont AM; Hauschild A; Espinosa E
    Am J Ther; 2015; 22(1):54-60. PubMed ID: 24176884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-G in melanoma: A new strategy to escape from immunosurveillance?
    Ugurel S; Reinhold U; Tilgen W
    Onkologie; 2002 Apr; 25(2):129-34. PubMed ID: 12006763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.